CA2609985A1 - Modulation des dysfonctionnements de la barriere cellulaire - Google Patents

Modulation des dysfonctionnements de la barriere cellulaire Download PDF

Info

Publication number
CA2609985A1
CA2609985A1 CA002609985A CA2609985A CA2609985A1 CA 2609985 A1 CA2609985 A1 CA 2609985A1 CA 002609985 A CA002609985 A CA 002609985A CA 2609985 A CA2609985 A CA 2609985A CA 2609985 A1 CA2609985 A1 CA 2609985A1
Authority
CA
Canada
Prior art keywords
opioid receptor
opioid
aeruginosa
receptor antagonist
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609985A
Other languages
English (en)
Inventor
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
The University Of Chicago
John C. Alverdy
Jonathan Moss
Mark W. Lingen
Patrick A. Singleton
Joe G.N. Garcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2006/007892 external-priority patent/WO2006096626A2/fr
Application filed by The University Of Chicago, John C. Alverdy, Jonathan Moss, Mark W. Lingen, Patrick A. Singleton, Joe G.N. Garcia filed Critical The University Of Chicago
Publication of CA2609985A1 publication Critical patent/CA2609985A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
CA002609985A 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire Abandoned CA2609985A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US68756805P 2005-06-03 2005-06-03
US60/687,568 2005-06-03
US73100905P 2005-10-28 2005-10-28
US60/731,009 2005-10-28
US76085106P 2006-01-20 2006-01-20
US60/760,851 2006-01-20
PCT/US2006/007892 WO2006096626A2 (fr) 2005-03-07 2006-03-07 Utilisation d'antagonistes opioides pour l'attenuation de la proliferation et de la migration des cellules endotheliales
USPCT/US2006/07892 2006-03-07
PCT/US2006/021604 WO2007053194A2 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Publications (1)

Publication Number Publication Date
CA2609985A1 true CA2609985A1 (fr) 2007-05-10

Family

ID=38006351

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609985A Abandoned CA2609985A1 (fr) 2005-06-03 2006-06-05 Modulation des dysfonctionnements de la barriere cellulaire

Country Status (3)

Country Link
EP (1) EP1901742A2 (fr)
CA (1) CA2609985A1 (fr)
WO (1) WO2007053194A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2368553T3 (en) 2003-04-08 2015-02-09 Progenics Pharm Inc Pharmaceutical preparation comprising methylnaltrexone
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
WO2007123865A2 (fr) * 2006-04-19 2007-11-01 Smith Jill P Traitement de maladies inflammatoires et ulcéreuses du côlon à l'aide d'antagonistes opioïdes
TWI553009B (zh) 2007-03-29 2016-10-11 普吉尼製藥公司 末梢性類鴉片受體拮抗劑及其用途
HUE025662T2 (en) 2007-03-29 2016-04-28 Wyeth Llc Peripheral opioid receptor and antagonists and their uses
CA2865389A1 (fr) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Formes cristallines et leurs utilisations
MX2010003660A (es) * 2007-10-05 2010-08-10 Toray Industries Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
EP2240489A1 (fr) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone
CA2719134C (fr) 2008-03-21 2015-06-30 The University Of Chicago Traitement avec des antagonistes des opioides et des inhibiteurs mtor
WO2010002576A1 (fr) 2008-07-01 2010-01-07 University Of Chicago Particules contenant un antagoniste de récepteur d'opioïde et procédés d'utilisation correspondants
CA2676881C (fr) 2008-09-30 2017-04-25 Wyeth Antagonistes de recepteurs opioides peripheriques, et leurs utilisations
PL3677261T3 (pl) 2010-09-23 2023-10-16 Leading BioSciences, Inc. Sposób podawania inhibitorów proteazy serynowej do żołądka
US10485798B2 (en) 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
KR102397379B1 (ko) 2014-03-25 2022-05-13 리딩 바이오사이언시즈, 인크. 자가소화의 치료용의 조성물
WO2024002335A1 (fr) * 2022-06-30 2024-01-04 Shanghai Yuguan Biotech Co., Ltd. Souche bacterienne vivante de pseudomonas sp.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863928A (en) * 1989-01-04 1989-09-05 Baker Cummins Pharmaceuticals, Inc. Method of treatment for arthritic and inflammatory diseases
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6194382B1 (en) * 1999-03-03 2001-02-27 Albert Einstein College Of Medicine Of Yeshiva University Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
US6384044B1 (en) * 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
CA2610951A1 (fr) * 2005-06-03 2006-12-14 The University Of Chicago Modulation d'interaction de pathogenes microbiens-cellules hotes

Also Published As

Publication number Publication date
WO2007053194A2 (fr) 2007-05-10
EP1901742A2 (fr) 2008-03-26
WO2007053194A3 (fr) 2007-08-09

Similar Documents

Publication Publication Date Title
US20140142133A1 (en) Modulation of cell barrier dysfunction
CA2609985A1 (fr) Modulation des dysfonctionnements de la barriere cellulaire
AU2012272815B2 (en) Treatment of proteinopathies
US20070059272A1 (en) Modulation of microbial pathogen-host cell interactions
JP5078885B2 (ja) Ｆｌｔ３阻害剤とファルネシル転移酵素阻害剤を用いたｆｌｔ３キナーゼの相乗的モジュレーション
Ye et al. Scutellarin inhibits caspase-11 activation and pyroptosis in macrophages via regulating PKA signaling
JP2009510047A (ja) 蝸牛興奮毒性によって誘導される耳鳴りを処置する方法
Clark et al. Inhibition of protein kinase C attenuates Pseudomonas aeruginosa elastase–induced epithelial barrier disruption
Urbauer et al. Mitochondrial metabolism in the intestinal stem cell niche—sensing and signaling in health and disease
WO2003090681A2 (fr) Effets synergetiques des inhibiteurs du facteur nf-kb de transcription nucleaire et d'agents anti-cancereux
JP2019513749A (ja) 衛生化及び麻酔用のｔｒｐｖ４及びｔｒｐａ１の小分子二重阻害剤
Broadley et al. Effects of dietary amines on the gut and its vasculature
CN103221043A (zh) 用于治疗神经元连接发育障碍的erk抑制剂
Wang et al. Chaperone heat shock protein 70 in nucleus accumbens core: a novel biological target of behavioural sensitization to morphine in rats
WO2019246298A1 (fr) Compositions et procédés pour la réduction ou le traitement de la fibrose
Shimazu et al. (−)-1-(Benzofuran-2-yl)-2-propylaminopentane enhances locomotor activity in rats due to its ability to induce dopamine release
JP2014208673A (ja) オピオイド拮抗薬による薬物誘発性嘔気の治療
EP3610869A1 (fr) Composition contenant du sarpogrélate en tant que principe actif, pour la prévention ou le traitement de la perte auditive neurosensorielle
US20210069295A1 (en) Galectins control mtor in response to endomembrane damage and provide a mechanism and target for the treatment of autophagy-related diseases
Whiteside et al. WAY‐318068: a novel, potent and selective noradrenaline re‐uptake inhibitor with activity in rodent models of pain and depression
EP2599488B1 (fr) Vicenin 2 et dérivés associés à utiliser en tant qu'agent antispasmodique et/ou prokinétique
KR101858055B1 (ko) 탐스로신을 유효성분으로 포함하는 인지기능 개선용 조성물
KR20230019387A (ko) 호노키올을 포함하는 조성물 및 이의 내피 기능장애 질환의 예방, 개선 및 치료 용도
Su et al. Evaluation of the Effects of E-Cigarette Aerosol Extracts and Tobacco Cigarette Smoke Extracts on Human Gingival Epithelial Cells
WO2023154014A1 (fr) Antagonistes nmdar prévenant le vieillissement et les troubles et maladies associées au vieillissement en augmentant l'activité du protéasome 20s

Legal Events

Date Code Title Description
FZDE Dead